Release Date: September 30, 2022
Expiration Date: September 30, 2023
Activity Overview
The management of breast cancer is evolving rapidly with new treatment options and new indications for approved agents emerging at a record pace. Novel agents and improved regimens coupled with more in-depth molecular and phenotypic subtyping are driving the future of breast cancer therapy. Current standards of care require the use of biomarkers and molecular assays to characterize each patient’s tumor as well as assessment of the benefit-risk ratio for individual therapeutic options in the context of patient comorbidities and preferences.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 21st Annual International Congress on the Future of Breast Cancer®, held in July 2022. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with breast cancer and putting recent clinical trial data into context. The program is designed to inform those who did not attend the live meeting and to help reinforce learnings for those who did.
Target Audience
This educational activity is intended for medical, surgical, and radiation oncologists involved in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer may also participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate results from genomic and/or molecular biomarker assays to characterize tumor subtype, assess risk, and individualize treatment selection for patients with breast cancer
- Incorporate evidence from recent clinical trials of systemic agents for the treatment of early-stage and metastatic breast cancer into personalized treatment plans to ensure optimal patient outcomes
- Assess emerging data from clinical trials of novel investigational agents for the treatment of breast cancer, and how these data may impact treatment algorithms
- Implement multidisciplinary team-based strategies for recognizing and managing treatment-related adverse events for patients with breast cancer in order to reduce risk of harm while maintaining efficacy
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
